

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2006/311600

A. CLASSIFICATION OF SUBJECT MATTER

A61K39/395(2006.01)i, A61K9/19(2006.01)i, A61K47/02(2006.01)i, A61K47/10(2006.01)i, A61K47/18(2006.01)i, A61K47/22(2006.01)i, A61K47/26(2006.01)i, A61K47/46(2006.01)i, A61P43/00(2006.01)i, G01N33/15(2006.01)i,
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K39/395(2006.01), A61K9/19(2006.01), A61K47/02(2006.01), A61K47/10(2006.01), A61K47/18(2006.01), A61K47/22(2006.01), A61K47/26(2006.01), A61K47/46(2006.01), A61P43/00(2006.01), G01N33/15(2006.01),

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2006
Kokai Jitsuyo Shinan Koho 1971-2006 Toroku Jitsuyo Shinan Koho 1994-2006

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS (STN), EMBASE (STN), MEDLINE (STN), JMEDPLUS (JDream2),
JST7580 (JDream2), JSTPLUS (JDream2)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	COCHLOVIUS B., Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody	1-6, 9, 14-19, 22
Y	and T cells, Journal of immunology, 2000,	10
A	Vol.165, No.2, pages 888 to 895	12, 13, 23, 24, 36-42
Y	WO 2004/019966 A1 (CHUGAI SEIYAKU KABUSHIKI KAISHA), 11 March, 2004 (11.03.04), Full text & EP 1541165 A1 & US 2006/058511 A1	10

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
17 August, 2006 (17.08.06)

Date of mailing of the international search report
29 August, 2006 (29.08.06)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2006/311600

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP 2003-515323 A (OXFORD BIOMEDICA (UK) LTD.), 07 May, 2003 (07.05.03), Claims; Par. No. [0208] & WO 2001/36486 A2 & EP 1242456 A2 & US 2003/083290 A1 & US 2004/131591 A1 & US 2004/265275 A1 & US 2006/014222 A1	10
Y	JP 2002-543822 A (SMITHKLINE BEECHAM CORP., US), 24 December, 2002 (24.12.02), Par. Nos. [0020], [0075] & WO 2000/69462 A1 & EP 1178829 A1	10
P,X	WO 2005/107784 A1 (CHUGAI SEIYAKU KABUSHIKI KAISHA, JP), 17 November, 2005 (17.11.05), Par. No. [0147]; example 1 (Family: none)	1-6, 9, 14-19, 22
A	KIPRIYANOV S.M., Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics, Journal of Molecular Biology, 1999, Vol.293, No.1, pages 41 to 56	12, 13, 23, 24, 36-42
A	Voelkel T., Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies, Protein Engineering, 2001, Vol.14, No.10, pages 815 to 823	12, 13, 23, 24, 36-42
A	Meng R., The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies, Clinical cancer research, 2004, Vol.10, No.4, pages 1274 to 1281	12, 13, 23, 24, 36-42
A	JAGER M., Folding and Assembly of an Antibody Fv Fragment, a Heterodimer Stabilized by Antigen, Journal of Molecular Biology, 1999, Vol.285, No.5, pages 2005 to 2019	12, 13, 23, 24, 36-42
A	KORN T., Recombinant bispecific antibodies for the targeting of adenoviruses to CEA- expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv, Journal of Gene Medicine, 2004, Vol.6, No.6, pages 642 to 651	12, 13, 23, 24, 36-42
A	KIPRIYANOV S.M., Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies, Journal of Molecular Biology, 2003, Vol.330, No.1, pages 99 to 111	12, 13, 23, 24, 36-42